November 22, 2025 a 08:38 am
BSX: Analysts Ratings - Boston Scientific Corporation
Boston Scientific Corporation, as a leader in the medical device sector, demonstrates robust potential in the market. The company’s consistent focus on innovation across its three segments—MedSurg, Rhythm and Neuro, and Cardiovascular—positions it strongly against competitors. Current analyst sentiment reflects confidence, with significant "Buy" recommendations dominating the landscape.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 25 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment development
Over the past months, analyst sentiment regarding Boston Scientific Corporation has remained largely positive, with minimal fluctuations in ratings. The predominance of "Buy" recommendations suggests sustained confidence in the company's market positioning. Notable observations include:
- The "Strong Buy" recommendation saw a slight drop from 12 to 7 in the past year.
- The total number of "Buy" ratings has remained stable with minor fluctuations around the value of 25.
- "Hold" ratings have shown a gradual decrease, indicating growing analyst confidence in the company’s prospects.
Percentage trends
Analyzing the data percentage-wise, a trend shift is observed with a minor increase in "Strong Buy" past values transitioning to stable "Buy" recommendations. Key points include:
- The "Strong Buy" percentage decreased from 15% to 5%, illustrating a shift to more moderate “Buy” ratings.
- "Buy" ratings now represent over 80% of total analyst opinions, indicating a solid consensus.
- "Hold" ratings represent about 7% currently, showing decreased caution amongst analysts.
Over the last 12 months, openness to purchasing BSX stock has increased, as shown by the consistent levels of strong positive ratings, with minimal to no inclination towards "Sell" ratings.
Latest Analyst Recommendations
The latest analyst recommendations for Boston Scientific Corporation reflect a steady consensus, with no significant changes in opinion. The stability is indicative of positive sentiment regarding future growth and overall company performance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-23 | Buy | Buy | Truist Securities |
| 2025-10-23 | Buy | Buy | Canaccord Genuity |
| 2025-10-23 | Buy | Buy | UBS |
| 2025-10-23 | Overweight | Overweight | Wells Fargo |
| 2025-10-23 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Changes in analyst opinions regarding Boston Scientific Corporation have been minimal but significant. Periodic upgrades underscore a flexible perspective in response to dynamic market conditions.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-08 | Outperform | Perform | Oppenheimer |
| 2025-04-16 | Buy | Hold | Needham |
| 2024-10-18 | Hold | Buy | Needham |
| 2024-02-01 | Buy | Neutral | Mizuho |
| 2022-05-27 | Buy | Hold | Needham |
Interpretation
The analytical landscape around Boston Scientific Corporation suggests a strong market conviction towards the company’s continual growth. The plethora of "Buy" ratings with minimal variance or retreat presents a self-assured perspective. Analysts appear to maintain a stable outlook, indicating substantial confidence in both short-term potential and long-term benefits of investing in BSX. The lack of significant "Sell" motions hints at positive market anticipation and reliability in future forecasts, enhancing overall investor confidence.
Conclusion
In summary, Boston Scientific Corporation continues to maintain a favorable market position supported by strong product diversification and innovative advancements. The stable "Buy" positioning by analysts endorses continued growth prospects. While "Strong Buy" recommendations have slightly tapered, ongoing positivity underlines broad market confidence. Despite minimal fluctuations, the investment landscape seems favorable with manageable risks, even amidst broader economic shifts. The stability of the analyst sentiment augurs well for forthcoming returns, making BSX a potentially compelling component in diversified portfolios.